心血管

订阅

MedSci主页 / 所有栏目 / 心血管

余红：干细胞治疗心血管疾病的研究进展

2015-11-11 佚名 生物谷

干细胞心血管
关注

11月05日，由生物谷主办的2015（第七届）干细胞技术与临床转化论坛在上海君衡城市酒店举行。来自浙江大学附属第二医院的余红教授在会议上发表了题为"干细胞治疗心血管疾病的研究进展"的精彩报告。 余红教授首先指出，干细胞移植可能是心血管疾病潜在的治疗手段，同时也指出目前骨髓干细胞医治疗效有待改善。他向与会观众介绍了他的团队所做的干细胞优化研究，提出： 1、缺氧预处理提高骨髓间充质干细胞移植治

11月05日，由生物谷主办的2015（第七届）干细胞技术与临床转化论坛在上海君衡城市酒店举行。来自浙江大学附属第二医院的余红教授在会议上发表了题为"干细胞治疗心血管疾病的研究进展"的精彩报告。

余红教授首先指出，干细胞移植可能是心血管疾病潜在的治疗手段，同时也指出目前骨髓干细胞医治疗效有待改善。他向与会观众介绍了他的团队所做的干细胞优化研究，提出：

1、缺氧预处理提高骨髓间充质干细胞移植治疗心肌梗死的疗效，主要通过瘦素发挥作用；

2、缺氧预处理干细胞移植安全有效，无致瘤性，致恶性心律失常等不良事件发生；

3、缺氧预处理骨髓干细胞是安全的，与常规培养骨髓干细胞相比，可在一定程度上改善心功能，延缓左室重构。

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=43638, encodeId=affd436389d, content=没什么新的内容, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Tue Nov 24 07:24:00 CST 2015, time=2015-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43288, encodeId=9f12432880c, content=赞！, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cf8b1663762, createdName=岳牙, createdTime=Mon Nov 16 19:57:00 CST 2015, time=2015-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43289, encodeId=6752432895c, content=赞！, beContent=null, objectType=article, channel=null, level=null, likeNumber=168, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cf8b1663762, createdName=岳牙, createdTime=Mon Nov 16 19:57:00 CST 2015, time=2015-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43154, encodeId=c6aa43154fe, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cab51623450, createdName=sanshengshi, createdTime=Sat Nov 14 10:22:00 CST 2015, time=2015-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380497, encodeId=557e138049e2a, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Fri Nov 13 01:10:00 CST 2015, time=2015-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1497928, encodeId=d901149e92823, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Fri Nov 13 01:10:00 CST 2015, time=2015-11-13, status=1, ipAttribution=)]
    2015-11-24 owlhealth

    没什么新的内容

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=43638, encodeId=affd436389d, content=没什么新的内容, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Tue Nov 24 07:24:00 CST 2015, time=2015-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43288, encodeId=9f12432880c, content=赞！, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cf8b1663762, createdName=岳牙, createdTime=Mon Nov 16 19:57:00 CST 2015, time=2015-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43289, encodeId=6752432895c, content=赞！, beContent=null, objectType=article, channel=null, level=null, likeNumber=168, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cf8b1663762, createdName=岳牙, createdTime=Mon Nov 16 19:57:00 CST 2015, time=2015-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43154, encodeId=c6aa43154fe, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cab51623450, createdName=sanshengshi, createdTime=Sat Nov 14 10:22:00 CST 2015, time=2015-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380497, encodeId=557e138049e2a, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Fri Nov 13 01:10:00 CST 2015, time=2015-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1497928, encodeId=d901149e92823, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Fri Nov 13 01:10:00 CST 2015, time=2015-11-13, status=1, ipAttribution=)]
    2015-11-16 岳牙

    赞！

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=43638, encodeId=affd436389d, content=没什么新的内容, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Tue Nov 24 07:24:00 CST 2015, time=2015-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43288, encodeId=9f12432880c, content=赞！, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cf8b1663762, createdName=岳牙, createdTime=Mon Nov 16 19:57:00 CST 2015, time=2015-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43289, encodeId=6752432895c, content=赞！, beContent=null, objectType=article, channel=null, level=null, likeNumber=168, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cf8b1663762, createdName=岳牙, createdTime=Mon Nov 16 19:57:00 CST 2015, time=2015-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43154, encodeId=c6aa43154fe, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cab51623450, createdName=sanshengshi, createdTime=Sat Nov 14 10:22:00 CST 2015, time=2015-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380497, encodeId=557e138049e2a, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Fri Nov 13 01:10:00 CST 2015, time=2015-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1497928, encodeId=d901149e92823, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Fri Nov 13 01:10:00 CST 2015, time=2015-11-13, status=1, ipAttribution=)]
    2015-11-16 岳牙

    赞！

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=43638, encodeId=affd436389d, content=没什么新的内容, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Tue Nov 24 07:24:00 CST 2015, time=2015-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43288, encodeId=9f12432880c, content=赞！, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cf8b1663762, createdName=岳牙, createdTime=Mon Nov 16 19:57:00 CST 2015, time=2015-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43289, encodeId=6752432895c, content=赞！, beContent=null, objectType=article, channel=null, level=null, likeNumber=168, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cf8b1663762, createdName=岳牙, createdTime=Mon Nov 16 19:57:00 CST 2015, time=2015-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43154, encodeId=c6aa43154fe, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cab51623450, createdName=sanshengshi, createdTime=Sat Nov 14 10:22:00 CST 2015, time=2015-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380497, encodeId=557e138049e2a, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Fri Nov 13 01:10:00 CST 2015, time=2015-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1497928, encodeId=d901149e92823, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Fri Nov 13 01:10:00 CST 2015, time=2015-11-13, status=1, ipAttribution=)]
    2015-11-14 sanshengshi

    赞

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=43638, encodeId=affd436389d, content=没什么新的内容, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Tue Nov 24 07:24:00 CST 2015, time=2015-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43288, encodeId=9f12432880c, content=赞！, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cf8b1663762, createdName=岳牙, createdTime=Mon Nov 16 19:57:00 CST 2015, time=2015-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43289, encodeId=6752432895c, content=赞！, beContent=null, objectType=article, channel=null, level=null, likeNumber=168, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cf8b1663762, createdName=岳牙, createdTime=Mon Nov 16 19:57:00 CST 2015, time=2015-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43154, encodeId=c6aa43154fe, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cab51623450, createdName=sanshengshi, createdTime=Sat Nov 14 10:22:00 CST 2015, time=2015-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380497, encodeId=557e138049e2a, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Fri Nov 13 01:10:00 CST 2015, time=2015-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1497928, encodeId=d901149e92823, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Fri Nov 13 01:10:00 CST 2015, time=2015-11-13, status=1, ipAttribution=)]
    2015-11-13 mashirong

    #研究进展#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=43638, encodeId=affd436389d, content=没什么新的内容, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Tue Nov 24 07:24:00 CST 2015, time=2015-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43288, encodeId=9f12432880c, content=赞！, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cf8b1663762, createdName=岳牙, createdTime=Mon Nov 16 19:57:00 CST 2015, time=2015-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43289, encodeId=6752432895c, content=赞！, beContent=null, objectType=article, channel=null, level=null, likeNumber=168, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cf8b1663762, createdName=岳牙, createdTime=Mon Nov 16 19:57:00 CST 2015, time=2015-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43154, encodeId=c6aa43154fe, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cab51623450, createdName=sanshengshi, createdTime=Sat Nov 14 10:22:00 CST 2015, time=2015-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380497, encodeId=557e138049e2a, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Fri Nov 13 01:10:00 CST 2015, time=2015-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1497928, encodeId=d901149e92823, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Fri Nov 13 01:10:00 CST 2015, time=2015-11-13, status=1, ipAttribution=)]
    2015-11-13 andy2090

    #血管疾病#

    0

相关资讯

Cell Transplantation：干细胞移植可能对阿尔茨海默症有效

世界上患阿尔茨海默病(AD)的民众日益增加,痴呆患者的数量也在迅速增加，到2025年，患病人数可能有1亿人,但还没有有效的治疗方案。 佛罗里达州坦帕市的研究人员认为，干细胞移植治疗或许为治疗AD的可行方法。为此，他们着手探究这一方法，将人类脐血细胞(HUCBCs)注入AD小鼠体内，追踪这些细胞在大脑等组织的分布和留存，更好地探究人类脐带血细胞(HUCBCs)治疗AD这一方法的安全性和可行性。研究人

Stem Cell Reports：科学家发现Prkci基因可控制干细胞的产生

1

徐国彤：视网膜下腔移植不同干细胞对大鼠视网膜变性的干预作用

11月06日，由生物谷主办的2015（第七届）干细胞技术与临床转化论坛在上海君衡城市酒店举行。来自同济大学医学院的徐国彤院长在会议上发表了题为"视网膜下腔移植不同干细胞对大鼠视网膜变性的干预作用"的精彩报告。 视网膜变性是以年龄相关性黄斑变性和视网膜色素变性为主的致盲眼病，在全球范围内属于最严重的眼部疾病之一。而近些年来应用视网膜下腔移植干细胞治疗视网膜变性在动物研究和临床试验中都取得了一定

母义明：干细胞治疗2型糖尿病的现状与未来

11月06日，由生物谷主办的2015（第七届）干细胞技术与临床转化论坛在上海君衡城市酒店举行。来自清华大学医学院、解放军总医院内分泌科的母义明主任参加了本次大会，并且在会上分享了关于"干细胞治疗2型糖尿病的现状与未来"的精彩报告。 母义明主任首先分析了我国的糖尿病患病趋势逐渐严峻，以及对于2型糖尿病（T2DM）病因、机理的研究仍没有突破性进展的现状。随后母义明主任介绍了他的课题组研究了间充质

Genes & Devel：为什么干细胞可以维持多潜能性？

图片来源：medicalxpress.com为什么干细胞研究这么火热，因为其具有多向性，可以转变成机体中任何类型的细胞，而这种潜能常常被研究者们用来移除机体损伤或病变的组织细胞，但控制干细胞具有多向潜能的机制目前还并不清楚。近日，发表在国际杂志Genes & Development上的一项研究论文中，来自基础科学研究院的研究人员利用小鼠的胚胎干细胞（mESCs）进行研究揭示了控制诱导多能干

PNAS：致死性前列腺癌细胞或具有干细胞样特性

图片来源：medicalxpress.com 近日，来自加州大学洛杉矶分校等处的科学家通过研究表明，引发致死性前列腺癌的细胞或许同正常前列腺组织中的组织特异性的干细胞共享了某些遗传特质，相关研究刊登于国际杂志Proceedings of the National Academy of Sciences上。 研究者Owen Witte教授指出，揭露癌症的细胞特性，即阐明癌细胞疯长和扩散的机制